Avidity Biosciences, Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses), averaging +7.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-1.18 | not reported | not reported | |
| Q1 FY26 | $-1.05 | $-0.97 | +7.6% | Beat |
Back to RNA overview · RNA holders · RNA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.